Sanofi launches generic version of arthritis drug Arava in USA

2 October 2015

French drug major Sanofi (Euronext: SAN) launched the generic version of Arava (leflunomide) tablets to treat rheumatoid arthritis (RA), through its US generics unit.

For people living with rheumatoid arthritis, leflunomide blocks autoimmune antibodies that reduce inflammation with the aim of improving mobility. Sanofi's authorized generic version is the same formulation as the branded Arava, for which the company holds the original patent.

Cary Yonce, vice president, general therapeutics and life cycle management, Sanofi, said: "The Arava authorized generic assures patients that they receive the same quality treatment of the original drug. We are committed to making authorized generics like Arava available and affordable to patients who need them."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK